Read by QxMD icon Read

cardio- oncology

Alicia Armour
No abstract text is available yet for this article.
December 2018: Journal of the American Society of Echocardiography
Lara F Nhola, Sahar S Abdelmoneim, Hector R Villarraga, Manish Kohli, Axel Grothey, Kimberly-Ann Bordun, Matthew Cheung, Ryan Best, David Cheung, Runqing Huang, Sergio Barros-Gomes, Marshall Pitz, Pawan K Singal, Davinder S Jassal, Sharon L Mulvagh
BACKGROUND: Cardio-oncology is a recently established discipline that focuses on the management of patients with cancer who are at risk for developing cardiovascular complications as a result of their underlying oncologic treatment. In metastatic colorectal cancer (mCRC) and metastatic renal cell carcinoma (mRCC), vascular endothelial growth factor inhibitor (VEGF-i) therapy is commonly used to improve overall survival. Although these novel anticancer drugs may lead to the development of cardiotoxicity, whether early detection of cardiac dysfunction using serial echocardiography could potentially prevent the development of heart failure in this patient population requires further study...
November 17, 2018: Journal of the American Society of Echocardiography
Raymond Russell
Current cancer therapy has led to tremendous improvements in outcomes. These therapies rely both on established therapies, such as anthracyclines and radiation, and molecularly-targeted therapies, such as tyrosine kinase inhibitors and immune modulators. Integrative care for patients with cancer must consider the potential effects of these therapies on a variety of organ systems, including the cardiovascular system. As a result, specialties such as cardio-oncology have developed to identify these effects, determine how to best monitor for these effects, and how to treat and ultimately prevent these effects while allowing the patient to receive the therapy they require for their cancer...
November 15, 2018: Journal of Nuclear Cardiology: Official Publication of the American Society of Nuclear Cardiology
Shambhabi Chatterjee, Shashi Kumar Gupta, Christian Bär, Thomas Thum
Cancer is the leading cause of morbidity and mortality in the United States and globally. Owing to improved early diagnosis and advances in oncologic therapeutic options, the number of cancer survivors increases steadily. Such efficient cancer therapies have also lead to alarming increase in cardiovascular complications in a significant proportion of cancer survivors, due to adverse cardiovascular effects such as cardiotoxicity, cardiac atrophy and myocarditis. This has emerged as a notable concern in the healthcare and given rise to the new field of cardio-oncology, which aims at understanding the processes that occur in the two distinct disorders and how they interact to influence the progression of each other...
November 9, 2018: American Journal of Physiology. Heart and Circulatory Physiology
Ying Liu, Yan-Li Zhang, Ji-Wei Liu, Feng-Qi Fang, Jian-Ming Li, Yun-Long Xia
No abstract text is available yet for this article.
November 5, 2018: Chinese Medical Journal
Vlad G Zaha, W Gregory Hundley, Joseph A Hill
No abstract text is available yet for this article.
August 14, 2018: Circulation
Dimitrios Farmakis, Kalliopi Keramida, Gerasimos Filippatos
No abstract text is available yet for this article.
October 17, 2018: European Journal of Heart Failure
Sean M Davidson, Sapna Arjun, Maryna V Basalay, Robert M Bell, Daniel I Bromage, Hans Erik Bøtker, Richard D Carr, John Cunningham, Arjun K Ghosh, Gerd Heusch, Borja Ibanez, Petra Kleinbongard, Sandrine Lecour, Helen Maddock, Michel Ovize, Malcolm Walker, Marlene Wiart, Derek M Yellon
Due to its poor capacity for regeneration, the heart is particularly sensitive to the loss of contractile cardiomyocytes. The onslaught of damage caused by ischaemia and reperfusion, occurring during an acute myocardial infarction and the subsequent reperfusion therapy, can wipe out upwards of a billion cardiomyocytes. A similar program of cell death can cause the irreversible loss of neurons in ischaemic stroke. Similar pathways of lethal cell injury can contribute to other pathologies such as left ventricular dysfunction and heart failure caused by cancer therapy...
October 11, 2018: Basic Research in Cardiology
Athanasios Koutsoukis, Argyrios Ntalianis, Evangelos Repasos, Efsthathios Kastritis, Meletios-Athanasios Dimopoulos, Ioannis Paraskevaidis
Cardio-oncology is a recently developed field in cardiology aimed at significantly reducing cardiovascular morbidity and mortality and improving quality of life in cancer survivors. Cancer survival rates have been constantly increasing, mainly because of the advent of new, more potent and targeted therapies. However, many of the new therapies - along with some of the older chemotherapeutic regimens such as anthracyclines - are potentially cardiotoxic, which is reflected increasingly frequently in the published literature...
August 2018: European Cardiology
Steven M Ewer
No abstract text is available yet for this article.
August 2018: European Cardiology
Stephen J H Dobbin, Alan C Cameron, Mark C Petrie, Robert J Jones, Rhian M Touyz, Ninian N Lang
Clinical outcomes for patients with a wide range of malignancies have improved substantially over the last two decades. Tyrosine kinase inhibitors (TKIs) are potent signalling cascade inhibitors and have been responsible for significant advances in cancer therapy. By inhibiting vascular endothelial growth factor receptor (VEGFR)-mediated tumour blood vessel growth, VEGFR-TKIs have become a mainstay of treatment for a number of solid malignancies. However, the incidence of VEGFR-TKI-associated cardiovascular toxicity is substantial and previously under-recognised...
September 18, 2018: Heart: Official Journal of the British Cardiac Society
Michal Laufer-Perl, Matthew Derakhshesh, Assi Milwidsky, Liat Mor, Dor Ravid, Nadav Amrami, Jack Sherez, Gad Keren, Yan Topilsky, Yaron Arbel
Cardiotoxicity from cancer therapy has become a leading cause of morbidity and mortality in cancer survivors. The most commonly used definition is cancer therapeutic related cardiac dysfunction defined as a left ventricular ejection fraction (LVEF) reduction of >10%, to a value below 50%. However, according to the recent American and European Society of Echocardiography, global longitudinal strain (GLS) is the optimal parameter for early detection of subclinical left ventricular dysfunction. The objective of this study was to evaluate the frequency of GLS reduction in patients with active cancer and its correlation to other echocardiographic parameters...
August 20, 2018: American Journal of Cardiology
Nilesh Pareek, Joaquim Cevallos, Pedro Moliner, Mit Shah, Li Ling Tan, Vicki Chambers, A John Baksi, Rajdeep S Khattar, Rakesh Sharma, Stuart D Rosen, Alexander R Lyon
AIMS: Cardio-oncology clinics optimise the cardiovascular status of cancer patients but there is a limited description of their structure, case mix, activity and results. The purpose of this paper is to describe the activity and outcomes of a cardio-oncology service, particularly with respect to supporting optimal cancer treatment and survival. METHODS AND RESULTS: We prospectively studied patients referred to our service from February 2011 to February 2016. New York Heart Association (NYHA) class and parameters of cardiac function were measured at baseline and after optimisation by our service...
September 6, 2018: European Journal of Heart Failure
Jenica N Upshaw
Patients with breast cancer have higher rates of cardiovascular disease than age-matched controls. Anthracyclines and trastuzumab increase the risk of heart failure (HF) and radiation increases the risk of ischemic heart disease, valvular disease and HF. Older age, low normal ejection fraction, history of coronary artery disease (CAD), cardiac risk factors, higher cumulative anthracycline exposure, combination anthracycline and trastuzumab and/or radiation all increase the risk of cardiac events post treatment...
August 2018: Gland Surgery
A J Teske, M Linschoten, J A M Kamphuis, W R Naaktgeboren, T Leiner, E van der Wall, J Kuball, A van Rhenen, P A Doevendans, M J Cramer, F W Asselbergs
Recent advances in the early detection and treatment of cancer have led to increasing numbers of cancer survivors worldwide. Nonetheless, despite major improvements in the outcome of these patients, long-term side effects of radio- and chemotherapy affect both patient survival and quality of life, independent of the oncological prognosis. Chemotherapy-related cardiac dysfunction is one of the most notorious short-term side effects of anticancer treatment, occurring in ~10% of patients. Progression to overt heart failure carries a strikingly poor prognosis with a 2-year mortality rate of 60%...
November 2018: Netherlands Heart Journal
Muhammad Sardar, Nasreen Shaikh, Saad Ullah Malik, Faiz Anwer, Patrick Lee, David Sharon, Margaret Hh Eng
BACKGROUND: Despite cancer being the second most common cause of death in the United States, more people are living longer after the diagnosis of cancer than before. Healthcare workers will be treating an increasing number of patients with cancer. Various studies have identified predictors of cardiac arrest in the general population, however, none have been done to identify such factors in cancer patients who form a more vulnerable group with lower survival rate following cardiac arrest...
June 18, 2018: Curēus
Elizabeth Riddell, Daniel Lenihan
Major advances in cancer therapy have resulted in an unprecedented improvement in patient survival for many cancers. Partially as a consequence of increased longevity, it has become evident that the cardiovascular system is frequently impacted by chemotherapy, radiation, and particularly certain targeted therapy. Cardiotoxicity continues to be a dose-limiting side effect of many chemotherapeutic agents including the anthracyclines. Early identification of patients at increased risk of cardiotoxicity or detecting cardiac injury at the earliest point will allow for initiation of cardio-protective strategies and hopefully prevent or reduce the need to modify life-saving cancer therapies...
July 2018: Current Problems in Cancer
Richard M Steingart, Y Chandrashekhar, Thomas H Marwick
No abstract text is available yet for this article.
August 2018: JACC. Cardiovascular Imaging
Jennifer Liu, Jose Banchs, Negareh Mousavi, Juan Carlos Plana, Marielle Scherrer-Crosbie, Paaladinesh Thavendiranathan, Ana Barac
Early recognition of cancer therapy-related cardiac dysfunction (CTRCD) provides an opportunity to mitigate cardiac injury and risk of developing late cardiac events. Echocardiography serves as the cornerstone in the detection and surveillance of CTRCD in patients during and after cancer therapy. Guidelines from professional societies and regulatory agencies have been published on approaches to surveillance, diagnosis, and treatment of CTRCD, although adoption as standard of care remains limited given the lack of evidence on the prognostic value of asymptomatic left ventricular (LV) dysfunction in the oncology population...
August 2018: JACC. Cardiovascular Imaging
Patrizio Lancellotti, Thomas M Suter, Teresa López-Fernández, Maurizio Galderisi, Alexander R Lyon, Peter Van der Meer, Alain Cohen Solal, Jose-Luis Zamorano, Guy Jerusalem, Marie Moonen, Victor Aboyans, Jeroen J Bax, Riccardo Asteggiano
Aims: Anticancer therapies have extended the lives of millions of patients with malignancies, but for some this benefit is tempered by adverse cardiovascular (CV) effects. Cardiotoxicity may occur early or late after treatment initiation or termination. The extent of this cardiotoxicity is variable, depending on the type of drug used, combination with other drugs, mediastinal radiotherapy, the presence of CV risk factors, and comorbidities. A recent position paper from the European Society of Cardiology addressed the management of CV monitoring and management of patients treated for cancer...
August 6, 2018: European Heart Journal
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"